Abstract
Acromegaly is an orphan and debilitating disease calling for specialized management by highly experienced multidisciplinary teams. Surgery is the only curative therapy and is regarded as first-line management in most newly diagnosed cases ( 1). Although surgical techniques have improved over recent decades, the surgical cure rates remain modest and steady even in experienced centers ( 2). Thereby, clinical treatment algorithms have changed markedly often applying primary medical therapy as a first- or second-line option in relation to surgery, guided by the development of biomarkers for responsiveness ( 3). However, despite improved awareness of rare diseases, the diagnostic delay is still considerable for acromegaly and reported to be 6 to 10 years in various series, thereby linked to morbidity and mortality ( 4). Thus, there is a need for improvements in diagnosis by the development of even more sensitive biomarkers. With the recent changes in overall management and the introduction and availability of medical therapy even in combination, overall mortality has declined and even normalized in larger series published during the last 15 years, as reviewed ( 3), in accordance with the most recent studies ( 5). However, comorbidities in acromegaly are often coupled to various degenerative processes and seem to be disappointingly steady ( 6). This relative paradox might be explained by the fact that despite sensitive biomarkers for disease control, up to a third of patients participating in real-life studies still seem to be inadequately treated, as a result of strict and modern criteria for biochemical control ( 1, 3). Another point in relation to the longstanding morbidity in acromegaly is the risk of harm by excessive surgery, traditional radiotherapy, and potential medical overtreatment ( 3).

This publication has 7 references indexed in Scilit: